Cargando…
Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder
OBJECTIVE: Determine the long-term effectiveness of quetiapine in combination with standard treatments in preventing relapses for patients with bipolar I disorders METHOD: Twenty-one outpatients with type I bipolar disorder who had inadequate responses to ongoing standard therapies were treated with...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1188063/ https://www.ncbi.nlm.nih.gov/pubmed/16026618 http://dx.doi.org/10.1186/1745-0179-1-7 |
_version_ | 1782124774741245952 |
---|---|
author | Hardoy, MC Garofalo, Alessandra Carpiniello, Bernardo Calabrese, JR Carta, MG |
author_facet | Hardoy, MC Garofalo, Alessandra Carpiniello, Bernardo Calabrese, JR Carta, MG |
author_sort | Hardoy, MC |
collection | PubMed |
description | OBJECTIVE: Determine the long-term effectiveness of quetiapine in combination with standard treatments in preventing relapses for patients with bipolar I disorders METHOD: Twenty-one outpatients with type I bipolar disorder who had inadequate responses to ongoing standard therapies were treated with add-on quetiapine in an open-label study. The quetiapine dose was increased until clinical response occurred. Illness response was assessed using the Clinical Global Impression (CGI) scale. Relapse rates before and during quetiapine treatment were compared by calculating incidence risk ratios. RESULTS: Quetiapine was added to ongoing standard therapy for 26 to 78 weeks. Thirteen patients received combination therapy for at least 52 weeks. The mean quetiapine dose received was 518 ± 244 mg/day. There were highly significant improvements in overall relapse rate, manic/mixed relapse rate, and depression relapse rate in the period during quetiapine treatment compared with the period before quetiapine was initiated. The calculated relative risk of relapse in the absence of quetiapine treatment was 2.9 overall (95% confidence interval, 1.5~5.6), 3.3 for manic/mixed relapse (95% confidence interval, 1.5~7.1), and 2.4 for depressive relapse (95% confidence interval, 1.3~4.4). The mean Clinical Global Impression scores improved significantly from baseline during 26 weeks of quetiapine treatment in 21 patients (p = 0.002) and remained significantly better during a 52-week treatment period in 13 patients (p = 0.036). CONCLUSION: Long-term treatment with quetiapine combination therapy reduced the probability of manic/mixed and depressive relapses and improved symptoms in patients with bipolar I disorder who had inadequate responses to ongoing standard treatment. |
format | Text |
id | pubmed-1188063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-11880632005-08-20 Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder Hardoy, MC Garofalo, Alessandra Carpiniello, Bernardo Calabrese, JR Carta, MG Clin Pract Epidemiol Ment Health Research OBJECTIVE: Determine the long-term effectiveness of quetiapine in combination with standard treatments in preventing relapses for patients with bipolar I disorders METHOD: Twenty-one outpatients with type I bipolar disorder who had inadequate responses to ongoing standard therapies were treated with add-on quetiapine in an open-label study. The quetiapine dose was increased until clinical response occurred. Illness response was assessed using the Clinical Global Impression (CGI) scale. Relapse rates before and during quetiapine treatment were compared by calculating incidence risk ratios. RESULTS: Quetiapine was added to ongoing standard therapy for 26 to 78 weeks. Thirteen patients received combination therapy for at least 52 weeks. The mean quetiapine dose received was 518 ± 244 mg/day. There were highly significant improvements in overall relapse rate, manic/mixed relapse rate, and depression relapse rate in the period during quetiapine treatment compared with the period before quetiapine was initiated. The calculated relative risk of relapse in the absence of quetiapine treatment was 2.9 overall (95% confidence interval, 1.5~5.6), 3.3 for manic/mixed relapse (95% confidence interval, 1.5~7.1), and 2.4 for depressive relapse (95% confidence interval, 1.3~4.4). The mean Clinical Global Impression scores improved significantly from baseline during 26 weeks of quetiapine treatment in 21 patients (p = 0.002) and remained significantly better during a 52-week treatment period in 13 patients (p = 0.036). CONCLUSION: Long-term treatment with quetiapine combination therapy reduced the probability of manic/mixed and depressive relapses and improved symptoms in patients with bipolar I disorder who had inadequate responses to ongoing standard treatment. BioMed Central 2005-07-18 /pmc/articles/PMC1188063/ /pubmed/16026618 http://dx.doi.org/10.1186/1745-0179-1-7 Text en Copyright ©2005 Hardoy et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Hardoy, MC Garofalo, Alessandra Carpiniello, Bernardo Calabrese, JR Carta, MG Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder |
title | Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder |
title_full | Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder |
title_fullStr | Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder |
title_full_unstemmed | Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder |
title_short | Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder |
title_sort | combination quetiapine therapy in the long-term treatment of patients with bipolar i disorder |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1188063/ https://www.ncbi.nlm.nih.gov/pubmed/16026618 http://dx.doi.org/10.1186/1745-0179-1-7 |
work_keys_str_mv | AT hardoymc combinationquetiapinetherapyinthelongtermtreatmentofpatientswithbipolaridisorder AT garofaloalessandra combinationquetiapinetherapyinthelongtermtreatmentofpatientswithbipolaridisorder AT carpiniellobernardo combinationquetiapinetherapyinthelongtermtreatmentofpatientswithbipolaridisorder AT calabresejr combinationquetiapinetherapyinthelongtermtreatmentofpatientswithbipolaridisorder AT cartamg combinationquetiapinetherapyinthelongtermtreatmentofpatientswithbipolaridisorder |